Chronic Lymphocytic Leukemia (CLL) Clinical Trial Monitoring

Why CLL trial monitoring matters in 2026

Chronic lymphocytic leukemia has undergone more therapeutic transformation in the last decade than almost any other hematologic malignancy. The introduction of ibrutinib in 2014, followed by acalabrutinib, zanubrutinib, venetoclax, and obinutuzumab, displaced chlorambucil and FCR-based chemotherapy as frontline standards. Today the field is moving fast again on two fronts:

• MRD-guided treatment-free remission: The central question is no longer whether targeted therapy works, but how to combine or sequence agents to achieve deep enough MRD negativity to allow safe treatment discontinuation — potentially approaching functional cure.
• Post-BTKi/venetoclax failure: A growing population of patients has now progressed through both covalent BTK inhibitors and venetoclax, creating demand for third- and fourth-line options: non-covalent BTK inhibitors (pirtobrutinib), BTK degraders (BGB-16673), CAR-T, and bispecific antibodies.

For pharma and biotech CI teams, the CLL Phase 3 pipeline is dense and moving quickly. Missing a new Phase 3 enrollment opening, a competitor's discontinuation, or a protocol amendment on a pivotal MRD-endpoint trial can mean weeks of lag in your intelligence picture.

BTK degraders: the next-generation BTK approach entering Phase 3

The most significant new entrant in the CLL pipeline is the BTK degrader class — heterobifunctional molecules that direct the BTK protein to E3 ligase complexes for proteasomal degradation, rather than merely inhibiting kinase activity. Degraders can overcome C481S resistance mutations that cause covalent BTKi failure, and may achieve more complete BTK suppression than inhibitors. BeOne Medicines (formerly BeiGene) has the most advanced clinical degrader program, with BGB-16673 now in five Phase 3 trials:

NCT ID	Comparison	Population	Status
NCT06846671	BGB-16673 vs. investigator's choice	CLL/SLL after covalent BTKi	Recruiting
NCT06973187	BGB-16673 vs. comparator	CLL (safety/efficacy extension)	Recruiting
NCT06970743	BGB-16673 vs. investigator's choice	CLL/SLL (additional cohort)	Recruiting
NCT07277231	Sonrotoclax + zanubrutinib	Untreated CLL/SLL (TFR goal)	Recruiting
NCT06943872	Sonrotoclax + zanubrutinib	Previously treated CLL	Recruiting

The combination of sonrotoclax (BGB-11417, BeOne's next-generation BCL-2 inhibitor) with zanubrutinib is particularly closely watched — this all-oral, fixed-duration doublet targets both BTK and BCL-2 to achieve deep MRD-negative remissions that could enable treatment-free remission without chemotherapy or antibody infusions.

Non-covalent BTK inhibitors: pirtobrutinib and nemtabrutinib

Pirtobrutinib (LOXO-305, Lilly) was the first non-covalent BTK inhibitor to demonstrate activity in patients who had progressed on covalent BTKi therapy, exploiting its binding mode that is unaffected by the C481S gatekeeper mutation. Three pirtobrutinib Phase 3 trials are now active:

• NCT05023980 — Pirtobrutinib vs. bendamustine + rituximab in treatment-naive CLL
• NCT04965493 — Pirtobrutinib + venetoclax + rituximab in CLL (Phase 3 combination)
• NCT05254743 — Pirtobrutinib vs. ibrutinib (head-to-head Phase 3 in CLL)

Nemtabrutinib (MK-1026, Merck) is a second non-covalent BTKi with three Phase 3 programs in CLL/SLL, testing monotherapy, venetoclax combinations, and chemoimmunotherapy comparisons. The ROCKET-CLL trial (NCT07342478, Newave Pharmaceutical) is a Phase 3 head-to-head comparison of rocbrutinib vs. pirtobrutinib — the first direct comparison of two non-covalent BTK inhibitors, with implications for the entire class.

MRD-guided therapy: the standard of the future

Minimal residual disease (MRD) measurement by flow cytometry or PCR has become central to CLL trial design. The hypothesis — that achieving undetectable MRD (uMRD4 or uMRD6) allows safe treatment discontinuation with durable responses — is being tested prospectively in multiple Phase 3 trials. Key programs include:

• NCT05057494 (AstraZeneca) — Acalabrutinib + venetoclax vs. venetoclax + obinutuzumab; MRD-guided treatment cessation endpoint
• NCT04075292 (AstraZeneca) — Acalabrutinib vs. chlorambucil + rituximab in older/less-fit patients
• NCT03701282 (NCI) — Venetoclax ± ibrutinib; prospective MRD assessment
• NCT07321652 (Alliance) — Sonrotoclax + acalabrutinib; testing BTKi + novel BCL-2i combination

Monitoring MRD endpoint readouts and protocol amendments — particularly changes to the uMRD threshold required for treatment discontinuation — is critical intelligence for any company developing a CLL therapeutic.

Selected active Phase 3 CLL trials

NCT ID	Sponsor	Agent / Comparison	Population	Status
NCT05254743	Lilly/Loxo	Pirtobrutinib vs. ibrutinib	Previously treated CLL	Recruiting
NCT05023980	Lilly/Loxo	Pirtobrutinib vs. BR	Treatment-naive CLL	Recruiting
NCT05624554	Merck	Nemtabrutinib vs. CIT	Treatment-naive CLL	Recruiting
NCT06136559	Merck	Nemtabrutinib vs. comparator	R/R CLL	Recruiting
NCT05947851	Merck	Nemtabrutinib + venetoclax vs. Ven+R	CLL	Recruiting
NCT05057494	AstraZeneca	Acalabrutinib + venetoclax vs. Ven+O	Previously treated CLL	Recruiting
NCT03336333	BeOne Medicines	Zanubrutinib vs. BR	Treatment-naive CLL	Active
NCT07342478	Newave	Rocbrutinib vs. pirtobrutinib	R/R CLL (ROCKET-CLL)	Recruiting

What DataLookout monitors for CLL

DataLookout pulls directly from the ClinicalTrials.gov API every day. For a CLL watch profile, configure:

• Condition keywords: "chronic lymphocytic leukemia", "CLL", "small lymphocytic lymphoma", "SLL", "BTK inhibitor CLL", "venetoclax CLL"
• Intervention keywords: "pirtobrutinib", "zanubrutinib", "acalabrutinib", "ibrutinib", "venetoclax", "nemtabrutinib", "BGB-16673", "sonrotoclax"
• Phase filter: Phase 1 only, Phase 2/3, or all phases
• Sponsor filter: Industry-sponsored only (for competitive intelligence) or all sponsors
• Status filter: Recruiting only, all active studies, or any status

How it compares to ClinicalTrials.gov RSS alerts

ClinicalTrials.gov does have a basic RSS/email notification system, but it has significant limitations for professional use:

• No phase filtering — you get every Phase 1 first-in-human study alongside major Phase 3 trials
• No sponsor type filtering — academic, NIH, and industry trials are mixed together
• No clear labeling of "new" vs. "updated" trials — everything looks the same
• No support for multiple simultaneous search profiles
• Difficult to set up and manage for non-technical users

DataLookout delivers filtered, labeled, and organized alerts — the intelligence layer on top of the raw data.

Who uses CLL trial monitoring

Competitive intelligence teams at BTKi and BCL-2 companies

Companies with CLL assets — whether a covalent BTK inhibitor, non-covalent BTKi, BCL-2 inhibitor, BTK degrader, or cellular therapy — need comprehensive daily coverage to track competitor trial openings, protocol amendments, and early-phase expansions. A competitor posting a new Phase 3 enrollment for a BTK degrader or a head-to-head pirtobrutinib trial may not generate a press release for weeks, but it appears on ClinicalTrials.gov within days of posting. DataLookout surfaces it the next morning.

Business development and licensing professionals

CLL remains a high-value indication for in-licensing. BD teams looking for combination partners, early-stage assets, or signals that a competitor's program is stalling use trial monitoring to identify opportunities. A Phase 1 trial showing early MRD-negative responses in relapsed/refractory CLL is often the first public data point before any conference presentation. Catching it when enrollment opens — not when the abstract appears at ASH — creates a meaningful head start on partnership conversations.

CROs and clinical operations teams

Contract research organizations managing CLL trials need to track the competitive enrollment environment. With 24 active Phase 3 trials recruiting from an overlapping patient population, site feasibility and patient availability are critical planning inputs. DataLookout gives CRO teams a daily view of who is recruiting, at what phase, and with what eligibility criteria — without logging into ClinicalTrials.gov manually each morning.

Frequently asked questions

How current is the CLL trial data?

Our pipeline fetches from ClinicalTrials.gov every morning. Studies posted or updated in the preceding 24 hours appear in that day's digest.

Can I track both CLL and SLL in the same profile?

Yes. Small lymphocytic lymphoma (SLL) is the same disease as CLL by a different name (based on disease presentation rather than biology), and most CLL trials enroll both. You can include "CLL" and "SLL" as keywords in a single watch profile to capture trials matching either term.

Does DataLookout cover international trials?

ClinicalTrials.gov includes trials conducted internationally. This covers major industry-sponsored programs worldwide, including CLL trials from BeOne Medicines, Janssen, AstraZeneca, and academic cooperative groups in Europe and Asia.

What is the difference between BTK inhibitors and BTK degraders?

Covalent BTK inhibitors (ibrutinib, acalabrutinib, zanubrutinib) bind irreversibly to the C481 residue of BTK's active site, blocking kinase activity. The C481S point mutation — common in relapsed/refractory CLL — disrupts this binding, causing resistance. Non-covalent BTK inhibitors (pirtobrutinib, nemtabrutinib) bind BTK in a reversible manner not dependent on C481, maintaining activity against C481S-mutant disease. BTK degraders (BGB-16673) go further — they recruit the proteasome to destroy BTK protein entirely, eliminating both kinase-dependent and scaffold functions that may contribute to treatment resistance. Monitoring each class separately requires distinct keyword strategies in your watch profiles.